Unlike biologics used for rheumatoid arthritis (TNF antagonists) and psoriasis (IL-17, IL-23 antagonists), the current biologics for SLE, especially with renal involvement, have shown only modest clinical benefits. This evidence concerns the gene TNF and systemic lupus erythematosus.